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Increased nephrotoxicity of gentamicin in pyelonephritic rats
DENIS BEAUCHAMP, ANDRE P0IRIER, and MICHEL G. BERGERON
Infectious Diseases Service, Le Centre Hospitalier de l'Université Laval, Québec, Québec, Canada
Increased nephrotoxicity of gentamicin in pyelonephritic rats. Multiple
factors may increase the nephrotoxic potential of aminoglycosides. We
studied gentamicin susceptibility of kidneys infected with E. coli.
Several parameters of renal function, histological changes on light and
electron microscopy, and drug levels in renal parenchyma were com-
pared in pyelonephritic and normal rats treated with low doses (10
mg/kg/Q8 hr for 3 days), or high doses (60 mg/kg/day for 14 days), of
gentamicin. A significant increase (P < 0.01) in 13-galactosidase and
protein excreted in urine over a period of 17 days associated with severe
changes in diuresis and osmolality was noted in the infected treated rats
(low doses) compared with normal, treated, infected or control animals.
Histological modifications compatible with gentamicin nephrotoxicity
were more persistent in the infected treated animals. A significant
decrease in '4C inulin (P < 0.01) and 3H-PAH clearance and secretion
(P < 0.02) was observed in the infected treated rats receiving high doses
of antibiotics. Cellular necrosis and tubular desquamation also were
more severe in this group. Gentamicin levels in the cortex and medulla
of infected animals were significantly higher than in the normals (P <
0.01) and might have been responsible for the increased toxicity noted
in the pyelonephritic animals. Infected kidneys appeared to be more
susceptible to the nephrotoxic potential of gentamicin.
Néphrotoxicité accrue de Ia gentamicine cbez des rats pyélonéphri-
tiques. De multiples facteurs peuvent accroItre le potentiel néphroxique
des aminoglycosides. Nous avons étudie la susceptibilité a la genta-
micine de reins infectés par E. coli. Diffdrents paramétres de Ia fonction
rénale, les changements histologiques en microscopie optique et élec-
tronique, et les niveaux de médicament dans le parenchyme renal ont
été compares chez des rats pyelonephritiques ou normaux, traités par
de faibles doses (10 mg/kg/8h pendant 3 jours), ou de fortes doses (60
mg/kg/jour pendant 14 jours) de gentamicine. Une élévation significa-
tive (P < 0,01) de Ia 3-galactosidase et des protéines excrétées dans les
urines sur une période de 17 jours, associées a des modifications
sévéres de la diurése et de l'osmolalité ont été notées chez les rats
infectés traités (faibles doses), par rapport aux animaux normaux
infectés et traités, ou aux contrôles. Des modifications histologiques
compatibles avec une ndphrotoxicité a Ia gentamicine ont été plus
persistantes chez les animaux infectés traités. Une baisse significative
de Ia clearance et Ia sécrétion de '4C inuline (P < 0,01) et de 3H-PAH(P < 0,02) a ete observée chez les rats infectés et traités recevant les
fortes doses d'antibiotique. La nCcrose cellulaire et Ia desquamation
tubulaire étaient également plus sévères dans cc dernier groupe. Les
niveaux de gentamicine dans le cortex et Ia médullaire des animaux
infectés étaient significativement plus hauts que chez les normaux (P <
0,01) et pourraient avoir été responsables de l'augmentation de toxicité
notee chez les animaux pyélonephritiques. Les reins infectés apparais-
saient plus susceptibles au potentiel nephrotoxique de Ia gentamicine.
Gentamicin is nephrotoxic. Following glomerular filtration,
this aminoglycoside is reabsorbed partially by the proximal
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tubular cells [1]. The first histologic alterations induced by
gentamicin on kidney ultrastructure is the appearance of lamel-
lar structure deposition in the lysosomes of these cells [21. In
fact, gentamicin has been shown to interfere with the normal
catabolism of phospholipids, leading to further cellular distur-
bance and necrosis [3}.
Many risk factors modulating the susceptibility of the kidney
to the toxic potential of aminoglycosides have been identified.
These include an already-damaged kidney [4], metabolic acido-
sis [5], potassium depletion [6], concomitant use of cephalospo-
rins [7], diuretics [8], or nephrotoxic agents including glycerol
[91, methoxyflurane [10], and mercuric chloride [11]. However,
the question of whether kidney infection triggers the
nephrotoxicity of aminoglycosides has not been solved. In fact,
severe and chronic pyelonephritis, which may affect both
proximal and distal tubules, cannot be excluded as a risk factor
that may increase the susceptibility of the nephron to aminogly-
cosides.
Our previous investigation has revealed a greater accumula-
tion of gentamicin in the cortex and medulla of pyelonephritic
animals than in the kidneys of non-infected animals [121.
Moreover, this study has shown that the pyelonephritic rats
treated with gentamicin had altered renal functions, while
normal treated rats had no sign of toxicity [121.
This investigation compares the nephrotoxic potential of
gentamicin in both normal and pyelonephritic rats. Several sensitive
parameters of renal injury [13], including urinary enzyme excretion,
proteinuria, diuresis, osmolality, and histology, were evaluated as
indices of early gentamicin toxicity in normal and infected animals.
Less sensitive parameters of renal damage, including changes in the
glomerular filtration rate, PAH clearance, and PAH secretion were
evaluated in all groups, as indices of more severe gentaniicin toxicity.
Gentamicin levels and colony counts in the renal parenchyma of
these animals were done to see ii drug levels and the intensity of the
infection could be correlated with signs of nephrotoxicity.
Methods
Pyelonephritis model
Pyelonephritis was induced in 200 g female Sprague-Dawley
rats by direct inoculation of the left kidney with 0.1 ml inoculum
containing i07 to 108 cfu of E. co/i Yale strain (Dr. V. Andriole,
Yale University, New Haven, Connecticut, USA) [14]. The
minimal inhibitory concentration of gentamicin for E. co/i was
1.6 rg/ml. The bacteria were injected directly into the medulla
through the upper and lower poles of the kidney [15]. This
inoculation produced bilateral pyelonephritis in all animals; a
severe pyelonephritis of the left kidney with extensive inflarn-
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mation and abscess formation was induced by the inoculation,
and a less severe infection of the right kidney with few foci of
inflammation and slight swelling of the organ due to the reflux of
infected urine into the right ureter and kidney was observed.
Basal urine cultures done on all animals were sterile.
Treatment
Two groups of animals were controls. They included infected
(I) and normal (N) rats that had their left kidneys injected with
0.1 ml sterile Mueller Hinton broth (MHB). The normal and
infected rats were assigned to two regimens: short-term treat-
ment where normal (G-30) and infected (IG-30) rats received a
10 mg/kg gentamicin (Schering Corp., Montreal, Canada) every
8 hr for 3 days, and long-term treatment where normal (G-60)
and pyelonephritic (IG-60) animals were treated with 60
mg/kg/24 hr for 14 days. In all animals, treatment was started
i.p. 24 hr after the induction of the pyelonephritis.
Enzymuria, proteinuria, diuresis, and osmolalities
Eight animals of each group were housed singly in metabolic
cages and allowed 3 days to adapt. Rats had free access to food
and water, and their weight was monitored daily. Both water
and food intake were recorded. Twenty-four-hr urine collection
was made under mineral oil on Days 3, 6, 8, 10, 14, and 17.
Collected urines were centrifuged at 2500 rpm for 15 mm. Urine
volume was measured and osmolality was evaluated by freezing
point depression. /3-galactosidase, a lysosomal enzyme, was
measured by the method of Maruhn [161 using as substrate
P-nitro-phenyl-/3-D-galactopyranoside dissolved in citrate
buffer 0.1M, pH 4. Proteinuria was measured using Lowry's
methodology [171.
To preclude the possibility that the detected enzyme was not
the product of bacterial destruction, 3-galactosidase from E.
coli (molecular weight 540,000) [181 was separated from 13-
galactosidase originating from kidney cells (molecular weight
80,000) [19] using a fine column (Sephadex type G-150,
Pharmacia Canada Ltd., Montreal, Québec, Canada).
Inulin and PAH clearance
In the short-term treatment experiments, renal function eval-
uation was made on Day 10 when enzymuria and proteinuria
were maximal and when histology was done, In the long-term
treatment group, renal functions were done at the end of
therapy.
Six rats of each group were anesthetized with pentobarbital
50 mg/kg (Nembutal, Abbott Laboratories, St-Laurent,
Québec, Canada). The left carotid artery and the right jugular
vein were canulated with PE-50 and PE-20 polyethylene tubing
(Clay Adams, Div. of Becton, Dickinson, New Jersey, USA),
for sampling blood and infusion, respectively. An initial bolus
of 1 ml NaC1 0.85% containing 14C-inulin (0.10 mCi/dl, New
England Nuclear, Montreal, Québec, Canada), 3H-PAH (0.50
mCiIdl, New England Nuclear), unlabelled inulin (1 mg/mI), and
PAH (10 mg/mI) was infused at a rate of 0.28 ml/min. This bolus
was followed by a continuous, immediate infusion of this
solution at 0.052 mI/mm. One hr later, urine was collected for
three sequential 30-mm periods from the right and left ureters,
canulated separately (PE-lO, Clay Adams), in order to evaluate
the right and the left kidney function of each animal.
Blood samples were taken at the beginning and the end of
each urine collection period. '4C-inulin and 3H-PAH were
measured in a liquid scintillation counter (Model LS 7500,
Beckman, Montreal, Quebec, Canada), on double labelled
program, with automatic quench correction. Glomerular filtra-
tion rate was determined by inulin clearance. PAH clearance
and PAH secretion were evaluated also.
Histology
Five right kidneys from each group receiving high or low
doses were processed for histological studies on the tenth day
of the experiments. In the long-term treatment groups, as in the
controls, histology was done on the last day of treatment, on
Day 20, and up to Day 30 of the experiment.
At the time of sacrifice, five animals of each group were
anesthetized. A midline abdominal incision was made and a 21
gauge butterfly needle was inserted into the aorta above the
renal arteries. Following a perfusion of 10 ml Krebs-Ringer
solution (pH 7.4) at 7 mI/mm, 100 ml of glutaraldehyde 2% (pH
7.4) was infused into the live animals. After the in vivo
glutaraldehyde fixation, the kidneys were excised and placed in
the same fixative for 2 hr. Cubes of 1 cubic millimeter were
taken from the cortex and outer medulla and left overnight in
the same fixative at 4°C. After washing with phosphate buffer
0. lM (pH 7.4), the cubes were further fixed in 2% osmium
tetroxide for 3 hr at 4°C, dehydrated in ascending grades of
alcohol, and embedded in araldite 502 resin. Thick sections (1
xm) were cut with a LKB ultratome III, stained with hot
toluidine blue and examined to identify gross lesions. Thin
sections double stained with alcoholic uranyl acetate and lead
citrate were examined using a blinded code on a Phillips 300
electron microscope (Scarborough, Ontario, Canada). Histolog-
ical damage induced by gentamicin was graded according to the
scheme developed by Gilbert et al where the severity of
changes observed were ranked on a 0 to 4+ scale [201.
Drug levels and colony counts
Twenty-four rats were used for these experiments.
Gentamicin levels were determined as described previously [21]
in the serum, cortex, and medulla of normal and infected
animals. Colony counts in whole kidney were estimated using
the same technique [14].
Statistics
Results, including enzymuria, proteinuria, osmolality, and
physiological studies, were compared using an analysis of
variance (ANOVA) for repeated measures. Comparison of
group means was done using the Duncan's multiple range test
with Kramer's adjustment for unequal frequencies [22]. Renal
tissue gentamicin concentrations were analyzed by Student's t
test.
Results
Enzymuria, proteinuria, diuresis, and osmolality
Figure 1 shows the 24-hr urinary excretion of /3-galactosidase
(/3-Gal) and proteinuria for all groups from 3 to 17 days after the
beginning of short-term therapy. In contrast with normal rats
(N), non-treated pyelonephritic rats (I), or normal treated
animals (G-30), the pyelonephritic rats treated with gentamicin
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Table 1. Diuresis and osmolality (mean SEM)8 of a 24-hr urine collected after induction of pyelonephritis
Diuresis, ml/24-hr
(IG-30) had a noticeable increase in their urinary /3-Gal and
protein excretion. The excretion of/3-galactosidase of the IG-30
group was maximal from Days 6 to 10, and was significantly
higher than in the other groups on Days 6, 8, and 10 (ANOVA
P < 0.01). Enzyme differentiation studies showed that the
/3-galactosidase was not the product of E. co/idestruction but of
kidney damage. Protein excretion was maximal on the tenth
day, and at that time was also significantly higher in the 10-30
animals than in the other groups (P <0.01). Compared to the
controls, infected, or treated rats, a decrease in the urine
osmolality and an increase in diuresis were observed in the
infected and treated animals (Table 1). These changes were
maximal (P <0.01) from Days 6 to 10. The diuresis in all groups
was correlated directly with water intake.
Contrasting the short-term experiments, there was no differ-
ence in /3-galactosidase or protein excretion, diuresis, and
osmolality between the infected treated (IG-60) and treated rats
(0-60) groups. Levels of enzyme and protein and changes in
diuresis and osmolality were maximal on Day 10 and were more
striking in the long-term than in the short-term treatment
groups. Table 2 summarizes the data on Day 10; the normal (N)
and infected animals (I) had significantly different values than
the 0-60 and IG-60 groups (P < 0.01).
Daily weights were measured in all animals. Weight loss (<
4%) was observed in the first 3 days in the infected (I) and
infected treated rats (IG-30, IG-60), but there was no difference
in weight gain between the third and the 17th day of the
experiment in all groups. Weight loss could be correlated with
food intake, which diminished in the first 3 days in the infected
and infected treated groups.
mu/in and PAH c/earance
In the short-term treatment experiments, there was no signif-
icant difference in inulin and PAH clearance between the
groups. Figure 2 illustrates renal function tests for both left and
right kidneys in the long-term treatment experiments. Com-
pared to the other groups, a significant decrease (P < 0.02) in
the CPAH and TPAH was observed in both kidneys of infected
treated animals (10-60). A significant reduction of the CINU
was noted in the left kidney of the IG-60 group (P < 0.01) when
compared with either the treated, infected, or normal animals.
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Fig. 1. Urinary 24-hr excretion of
13-galactosidase and proreinuria in rats after
beginning treatment. Symbols are: s—., normal
rats; o—o, pyelonephritic rats; u—u, normal rats
treated with gentamicin 10 mg/kg Q8 hr for 3
days; —, infected rats given G-30 treatment.2 4 6 8 10 12 14 16 18
Days
N
G-30
IG-30
N
0-30
IG-30
3 6
Day
8 10 14 17
7.2 (O.5)8b
12.4(3.2)"
4.9 (0,8)8
8.0 (l.5)8b
75 (07)8
6.0 (1.2)8
5.7 (l.0)a
15.1 (2.0)'-'
8.1 (0.6)8 8.1 (1.0)8
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8 10 14 17
1581 (171)8
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1320 (121)"
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Abbreviations are: N, normal animals; I, infected; G-30, treated with 10 mg/kg/Q8 hr of gentamicin for 3 days; IG-30, infected treated animals.
a For a same day, means followed by a common letter are not significantly different at the 1% level, as shown by the Duncan's multiple range
test.
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Table 2. Diuresis, osmolality, protein, and 3-galactosidase (mean SEM)a excreted in a 24-hr urine on Day 10 after induction of pyelonephritis
Diuresis
ml/24 hr
Osmolality
mOsm/kgH2O
Protein
mg/24 hr
/3-galactosidase
mpJ24 hr
N 8.1 (1.0)a 1982 (183) 48.1 (5.1)a 61.6 (5.0)a
I 10.7 (2.4)a 1320 (121)' 643 (99)ab 50.9 (7.6)a
G-60 26.1 (4.9)" 610 (164)C 92.2 (l15)b 169.9 (38.4)"
IG-60 26.3 (75)b 540 (115) 87.9 (77)b 183.4 (22.4)"
CINU
mi/mm
CPAH
mi/mm
TPAH
moles/min
RL R L RL R L RL RL R L RL
N G-60 IG-60 N G-60 G-60
Fig. 2. Glomerular filtration rate (CINU), PAH clearance (CPAH), and PAH secretion (TPAH) of right (R) or left (L) kidneys in groups of rats defined
previously. Values for CINU and CPAH are for 100 g body wt.
Histology
In the controls, except for the presence of inflammatory cells
in the interstitial space, the non-treated right infected kidneys
did not reveal any major histological change. No myelin figure
nor enlarged lysosome could be seen at that time in this
non-treated group, but severe histological signs compatible with
pyelonephritis were present on Day 20 and thereafter in the
right kidney infected by reflux.
No histological modification on light and electron microscopy
was noted on Day 10 in the kidneys of normal rats treated with
gentamicin (G-30). In contrast, cells containing large and nu-
merous lysosomes with myelin figures were observed in the
kidneys of IG-30 rats. Cellular debris and numerous myelin
figures were observed in the tubular lumen of these animals.
No signs compatible with gentamicin therapy or pyelonephri-
tis were observed in the sterile broth injected controls. Table 3
illustrates histological scores observed in the different groups
based on the classification of Gilbert et al [201. Grade I changes
were noted in the right kidney of all five infected and treated
(IG-30) animals studied, while none of the other groups had any
histological modifications compatible with gentamicin toxicity.
Typical histological signs of gentamicin toxicity were seen on
Table 3. Microscopic proximal tubule changes [20] in the right
kidneys of normal and pyelonephritic rats given low and high doses
of gentamicin on Day 10
No.
Grade of proximal tubule changea
Light microscopy Electron microscopy
N
I
G-30
IG-30
G-60
IG-60
5
5
5
5
5
5
0
0
0
1
2
2
0
0
0
1
3
3
Abbreviations are: No., number of animals studied; N, normal; I,
infected; G-30, normal rats treated with 10 mg/kg Q8 hr for 3 days;
IG-30, pyelonephritic rats given G-30 treatment; G-60, normal rats
treated with 60 mg/kg Q24 hr for 14 days; IG-60, pyelonephritic rats
given G-60 treatment.
a Pathological changes described were observed in all animals in each
group.
Day 10 of the experiment on light microscopy in both the G-60
and IG-60 groups (Table 3). However, 15% (19/130 counted
tubules) of the proximal tubules observed in the IG-60 kidneys
Abbreviations are: N, normal animals; I, infected, G-60, normal animals treated with 60 mg/kg/day for 14 days; IG-60, infected animals treated
with 60 mg/kg/24 hr for 14 days.
a Means followed by a common letter are not significantly different at the 1% level, as shown by the Duncan's multiple range test.
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Table 4. Day 10 concentrations of gentamicin in cortex and medulla of normal and pyelonephritic kidneys of treated animals
Cortex
p-gig
Medulla
p-gig
Low dose High dose Low dose High dose
Normal kidneys
Pyelonephritic left kidneys
Pyelonephritic right kidneys
46 (7)]
173 (24)
163 (32)J
P < 0.01
165 (38)]
131 (36) F
86 (l4)J
NS
9 (2) ]
f4 (11) P < 0.01
69 (16) J
26 (6)1
16 (4)
15 (5)J
NS
Definitions are: Low dose, 10 mg/kg Q8 hr; high dose, 60 mglkg Q24 hr.
a Standard deviation, NS, not significant.
Table 5. Percentage of kidneys sterilized and log CFU at Day 10
(sEM) in animals receiving short- or long-term therapy with
gentamicin
Left Right
Sterility Log CFU Sterility Log CFU
% g % g
I 0 6.3 (0.2) 0 4.6 (0.2)
IG-30 0 5.4 (0.5) 10 3.0 (0.3)
IG60a 100 0 100 0
Abbreviations are the same as previous tables.
a In the high-dose experiments, 100% of the kidneys were still sterile
at Days 15, 20, and 30.
had epithelial necrosis and desquamation on Day 10 of treat-
ment, while these changes were observed in only 5% (7/130
counted tubules) (P < 0.01) of the tubules of the G-60 kidneys.
At the end of long-term treatment, changes were less severe
than on Day 10, and we observed the presence of regenerative
cells in both groups (G-60 and IG-60). The regeneration process
was almost complete by Day 20 when less than 1% of the
proximal tubule had epithelial necrosis and desquamation,
while on Day 30 of the experiment, none of the tubule was
necrotic.
Gentamicin levels and colony counts
Peak 1-hr serum levels following the last 10 mg/kg dose
administered on Day 3 were 12.1 (± 0.8) p-g/ml in normal and
19.0 (± 2.3) in infected rats. After the last 60 mg/kg doses, the
peak levels were 45.6 (± 3.1) p-g/ml in the normal and 59.4 (±
4.9) in the infected rats. Table 4 depicts the levels of gentamicin
on Day 10 of the experiment in both cortex and medulla of
animals receiving low and high doses of gentamicin. At the time
where renal levels were done, we could not detect any ami-
noglycosides in serum (< 0.2 p-gIml). When compared with the
non-pyelonephritic animals, significantly higher levels of anti-
biotics were observed in both kidneys of infected animals
treated with 10 mg/kg doses (P < 0.01). In the 60 mg/kg treated
rats, the renal levels were identical in both normal and
pyelonephritic rats and were lower than in the low-dose treated
rats. While 100% of the left kidneys and 90% of the right
kidneys were still infected following short-term therapy (Table
5), all of the left and right kidneys were sterilized on Days 10,
15, 20, and 30 in the long-term treatment group.
Discussion
These results support the hypothesis that pyelonephritic
kidneys are more susceptible than normal kidneys to the
nephrotoxic potential of gentamicin. The use of two therapeutic
regimens allowed us to study both very sensitive markers of
tubular damage and late manifestations of renal injury. Depend-
ing on the more or less sensitive criteria used to evaluate
nephrotoxicity, infected treated animals showed signs of renal
damage that were more striking than those observed in normal
treated rats. In the short-term treatment experiments, major
changes in urine osmolality, diuresis, /3-galactosidase and pro-
tein excretion associated with concomitant histopathological
changes were detected in the pyelonephritic treated animals,
but the dosage used was insufficient to induce changes in GFR,
a late manifestation of the nephrotoxocity of aminoglycosides
[23, 24].
In the long-term treatment experiments, inulin, PAH clear-
ance, and PAH secretion were affected more severely in the
infected treated animals, but sensitive markers of renal injury
could not discriminate between changes occurring in normal
and infected treated animals. These observations are consistent
with others that show high doses of gentamicin given for a long
period are necessary to decrease GFR and modify PAH trans-
port [24, 25].
Although both normal and infected animals treated with high
doses of gentamicin showed similar histopathological changes,
the percentage of tubules where these changes occurred was
significantly higher in the pyelonephritic rats, suggesting that
the infected kidney may be more susceptible to the nephrotoxic
potential of aminoglycosides. The possibility that renal infec-
tion might have delayed the regeneration process was ques-
tioned, but, at least in the high doses experiments where we did
observe regenerative cells, we could not follow the speed of
regeneration in normal treated and pyelonephritic treated kid-
neys using conventional histology. Others have shown that
pathological changes were very severe by Day 10 [26, 27], and
the regeneration process started thereafter [27, 28]. By Day 20,
the regeneration was almost complete [27, 29], and all the
tubules were normal on Day 30.
The mechanism by which aminoglycosides did induce renal
toxicity in our study is not well understood [3, 30]. Factors
other than infection should be considered. Although this study
was not designed to compare the frequency of administration on
nephrotoxicity, the use of TID and QD administration of
gentamicin should be considered as another factor modulating
nephrotoxicity. As shown by Bennett et al [31], multiple doses
of a specific daily amount of aminoglycosides were generally
more toxic than a single daily administration of the same
quantity. In our short- and long-term experiments, both daily
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doses and duration of therapy were different, so no conclusion
can be drawn on whether an intermittent daily administration is
more toxic than a single daily dose.
Gender is another risk factor that has to be considered in both
human experimentation and animal nephrotoxicity models.
Data from Bennett et a! [321 have shown a significantly greater
incidence of acute tubular necrosis in male than in female rats.
On the other hand, Kourilsky et al [331 have observed a higher
incidence of interstitial inflammation in female rats treated with
gentamicin. Our study used female rats exclusively, so the
decrease in renal function noted in animals treated with high
doses of gentamicin was due more likely to tubular damage than
to interstitial inflammation. Moreover, we have not observed
spontaneous pyelitis in untreated female rats. This and previous
studies [12, 141 have used female Sprague-Dawley pyelonephri-
tis models. In fact, it was in this model that we first discovered
evidence that infection might potentiate nephrotoxicity of
gentamicin [34]. Moreover, two recent reports by Kourilsky et
al [33] and Moore et al [35] seem to suggest that human females
have a higher incidence of aminoglycosides toxicity.
Although there is not necessarily an association between
levels of antibiotics in the renal parenchyma and renal toxicity,
most investigators consider high renal levels of antibiotics as
potentially nephrotoxic [301. The previous observations of
Bergeron et a! [121 and this study, which demonstrates again
that the infected renal parenchyma accumulated more
gentamicin than the normal kidney, suggest that these high
levels of aminoglycosides in both the cortex and medulla of
pyelonephritic rats might have contributed to the renal impair-
ment observed in these animals. The increase in aminoglyco-
side levels was very striking in the low-dose experiments
(IG-30), a drug regimen that could not sterilize the kidneys,
supporting the idea that infection modifies the intrarenal distri-
bution of gentamicin and may potentiate the nephrotoxic ca-
pacity of this agent.
Serum levels were undetectable at the time of kidney extrac-
tions for tissue levels, but one cannot exclude the possibility
that higher serum levels, which were observed on the last day of
therapy (Day 3), could have been associated with greater
tubular reabsorption with resultant higher cortical concentra-
tions of aminoglycosides, a key factor in inducing greater
toxicity in the pyelonephritic model. The reason for the notice-
able differences between the infected (19.0 xgIml) and non-
infected (12.1 xg/ml) is not clear, but recent data from our
laboratory [36] and from Wilson, Moore, and Eakle [37] in
horses suggest that endotoxin may modify the pharmacokinetic
of antibiotics and increase serum levels. For the low-dose
experiments where infection was still active at the time when
serum levels were taken, we cannot exclude the possibility that
endotoxin might have been liberated from the infected site.
Volume contractions in the infected animals cannot be ex-
cluded as an explanation for the higher serum levels. Further,
we cannot eliminate the possibility that in the acute phase of
infection there might have been a transient diminution in the
glomerular filtration rate that could have contributed to the
elevated aminoglycoside levels in serum.
Following high doses of gentamicin, there was no difference
in the levels of drugs in the kidneys of normal and sterilized
pyelonephritic kidneys, suggesting again that in the low-dose
experiments, active infection has modified the intrarenal
pharmacokinetic of gentamicin [12].
The combined action of high levels of gentamicin and of infection
in the renal parenchyma might have been more toxic to renal cells
than either of those factors taken individually. Even though most of
the toxicity of aminoglycosides has been attributed to proximal
tubular cell damage [1], disturbed concentrating ability of the kidney,
also a function of the distal nephron, has been shown as one of the
early signs of nephrotoxicity associated with gentamicin [2]. In fact,
levels of gentamicin in the medulla may persist for long periods
following cessation of therapy [21] and, as demonstrated again in this
study, the medullary levels were much higher in the infected than in
the normal rats. In addition to the possible gentamicin effect on the
concentrating ability of the kidney [38], active infection [39], and
tissue damage secondary to pyelonephritis or even endotoxin [40],
with or without the presence of bacteria in the renal parenchyma,
could have contributed to the concentrating defects observed in
pyelonephritis. Aminoglycosides then might diminish further the
already disturbed urinary concentrating ability of the pyelonephritic
kidneys. Moreover, water losses, presumably associated with potas-
sium and sodium losses, cannot be excluded as potential factors in
increased nephrotoxicity. Sodium and potassium depletion has been
shown to increase the toxic potential of gentamicin [6, 41]. Nor can
changes in extracellular volume secondary to acute pyelonephritis be
overlooked as one of several variables that might have modulated the
nephrotoxicity of the aminoglycosides.
Proteinuria, which can be observed in pyelonephritis, is an
early manifestation of gentamicin nephrotoxicity [26, 42]. In the
infected treated animals, it may be postulated that proteins in
the urine might have resulted from the combined action of
gentamicin and infection on proximal tubule [26], and infection
in the distal elements of the nephron [43]. Protein leakage
through the glomerula, although possible [26], seems unlikely to
most investigators who believe that following aminoglycosides
proteins leak through the tubular cells [26, 42].
Primary in these findings of the infected treated rats is the
significant modification in renal function and enzyme excretion,
associated with concomitant histological modifications compat-
ible with an increased gentamicin nephrotoxicity. We have
shown, as have Patel et al [44], that there is a good correlation
between the level of /3-galactosidase excreted in the urine and
damage to the lysosomes. These enzymes were not the product
of bacterial destruction [181, but most likely originated from
lysosomal damage in tubular cells [19]. As more gentamicin was
given [45], the excretion of J3-galactosidase increased. The mere
increase in the amount of aminoglycosides in the cortex of the
infected treated animals is probably sufficient to explain the
anomalies observed, but one should consider the possibility
that endotoxin or other bacterial products liberated during
antibiotic therapy [46] might act concomitantly on tubular cells
to potentiate the toxicity of gentamicin. It might be speculated
that endotoxin, which is known to affect lysosomes [33, 47] and
which can, as does gentamicin, inhibit mitochondrial enzymes
[48], block receptors [47, 49], and decrease the activity of Na
K ATPase [50, 51], could act synergistically with the amino-
glycoside to induce tubular changes. We are studying now
whether kidneys infected with enterococci, a pathogen without
endotoxiri, are as susceptible to aminoglycosides as those
infected by E. co/i.
In addition to the combined action of high levels of
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gentamicin and of bacteria on kidney cells, one cannot exclude
the influence of the pathological process of pyelonephritis on
the dynamic interaction between aminoglycosides and kidney
cells [43]. Even in the absence of active bacterial infection [52]
observed in the high-dose experiments, where kidneys were
sterilized by therapy, renal inflammation might affect mem-
brane permeability, cause local ischemia, or induce the libera-
tion of several mediators of inflammation that may make kidney
cells more susceptible to aminoglycoside toxicity [341.
Whether synergism exists between pyelonephritis and ami-
noglycosides that would produce nephrotoxicity is diflicult to
determine. Recent work by Moore et al [35] could not identify
specific infections as a risk factor for aminoglycosides-induced
nephrotoxicity, although a correlation with septicemia was
observed for ototoxicity [53]. Future analyses of kidney infec-
tions might define more specifically the interaction between
aminoglycosides and infected kidney cells.
Whatever the mechanism involved, renal infection should be
considered an additional risk factor involved in the increased
susceptibility of the kidney to aminoglycosides.
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